Actively Recruiting
PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
Led by University Health Network, Toronto · Updated on 2025-06-25
30
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Multiple myeloma is a disease mainly located in participants bones. Usually a participants physician arrives at this diagnosis by doing blood tests and ordering standard of care imaging tests (18F-FDG PET/CT and maybe additional MRI) to see how many bones (and/or other organs) are affected. While these two imaging tests are already very good, recent research indicates that even more precise imaging methods could be used to diagnose participants disease more precisely. The purpose of this study is to learn if a combined PET/MR scan with a new radiotracer, \[68Ga\]Ga-PentixaFor, can provide more accurate and precise diagnostic information in patients with Multiple Myeloma, a type of cancer primarily affecting the bones. This study aims to improve the accuracy of diagnosing and monitoring Multiple Myeloma using more advanced imaging techniques.
CONDITIONS
Official Title
PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient older than 18 years of age
- Clinical diagnosis of nonsecretory, oligosecretory, or suspected extramedullary Multiple Myeloma based on IMWG criteria
- No treatment received beyond first course
You will not qualify if you...
- Contraindications for MRI or 18F-FDG PET/CT imaging according to institutional guidelines
- Pregnancy
- Inability to lie still in prone position during MRI or PET/CT for at least 30 minutes
- Unwillingness to use contraception during the study
- Breastfeeding women
- Inability to provide consent
- Known allergy or hypersensitivity to any component of [68Ga]Ga-PentixaFor
- Diagnosis of any other malignant hemato-oncological disease such as lymphoma or leukemia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Health Network
Toronto, Ontario, Canada, M5G 2N2
Actively Recruiting
Research Team
P
Patrick Veit-Haibach, MD
CONTACT
V
Vishal Kukreti, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here